Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 dose-ranging study in systemic lupus erythematosus
MOH_2017-12-26_001911Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of deucravacitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary endpoint not reported. Started Dec 2017; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2017-12-26_001911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-26_001911.